Evaluation of C-reactive protein in patients with peripheral arterial disease. Modifications with antiplatelet drug treatment;Valoración de la proteína C reactiva en pacientes con arteriopatía periférica. Modificaciones con tratamiento antiagregante

Angiologia

Volumn 57, Issue 1, 2005, Pages 5-18

  Puras Mallagray, Enrique ^a   Cancer Perez S ^a   Lujan Huertas S ^a   Gutierrez Baz M ^a   Perera Sabio, M ^a   Alfayate Garcia J M ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

Author keywords

C reactive protein; Cardiovascular risk; Clopidogrel; Inflammation; Metabolic syndrome; Peripheral vascular disease

Indexed keywords

ANTITHROMBOCYTIC AGENT; C REACTIVE PROTEIN; CLOPIDOGREL;

ARTERY DISEASE; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; STATISTICAL ANALYSIS;

EID: 23044436175     PISSN: 00033170     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0003-3170(05)74915-4     Document Type: Article

References (26)

1. Riambau V, Piñol C. Claudicación intermitente: revision de una enfermedad de prevalencia creciente (II): Tratamiento. Med Clin 1998; 110: 220-7.
2. Dormandy J, Mahir M, Ascady G, Balsano F, De Leeuw P, Blombery P, et al. Fate of the patient with chronic leg ischaemia. A review article. J Cardiovasc Surg (Torino) 1989; 30: 50-7.
3. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-6.
4. Comité de Redacción de los protocolos. Comité de prevención y tratamiento de la enfermedad tromboembólica (y V). Terapéutica antitrombótica en la enfermedad arterial periférica. Med Clin 1994; 103: 470-2.
5. Riambau V, Piñol C. Claudicación intermitente: revisión de una enfermedad de prevalencia creciente (I): Clínica, etiología, epidemiología, historia natual y diagnóstico. Med Clin 1998; 110: 191-7.
6. Pintó X, Fiol C, Simeón JM, Capdevila JM, Barjau E, Argimón JM, et al. Factures de riesgo de la arteriopatía de las enfermedades inferiores: factures lipídicos y no lipídicos. Med Clin 1997; 109: 41-4.
7. Antiplatelet Trialist' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infaction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1988; 296: 320-31.
8. Gent M. A systematic overview of randomized trials of antiplatelet agents for the prevention of stroke, myocardial infarction, and vascular death. In Hass WK, Easton JD, eds. Ticlopidine, platelets and vascular disease. New York: Springer-Verlag; 1993. p. 99-116.
9. Caprie Steering Committee. A readomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
10. Roal HE, Barstad RM, Kierulf P. Phase I study-clopidrogel-a platelet inhibitor which inhibits thrombogenesis in human non-anticoagulated blood independently of blood flow conditions. Thromb Haemost 1993; 69: 1240.
11. Bainton D, Sweetnam P, Baker I, Elwood P. Peripheral vascular disease: consequence for survival and association with risk factors in the Speedwell prospective heart disease study. Br Heart J 1994; 72: 128-32.
12. Erren M, Reinecke H, Junker R, Kerber S, Breithardt G, Assmann G, et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol 1999; 19: 2355-63.
13. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Henneskens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998; 97: 425-8.
14. Liuzzo G, Biasucci LM, Gallimore JR, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331: 417-24.
15. Albert CM, Jing Ma, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002; 105: 2595-9.
16. Rossi E, Biasucci LM, Liuzzo G, Grieco G, Maseri A. Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein. Circulation 2002; 105: 800-3.
17. Cha JK, Jeong MH, Lee KM, Bae HR, Lim YJ, Park KW, et al. Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. J Thromb Thrombolysis 2002; 14: 145-50.
18. Hermann A, Rauch BH, Braun M, Schror K, Weber AA. Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression and inhibition by clopidogrel. Platelets 2001; 12: 74-82.
19. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn s, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997; 26: 517-38.
20. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. Circulation 2003; 107: 391.
21. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363.
22. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. Circulation 2003; 107: 499-511.
23. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflamation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
24. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al, for the Cholesterol And Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998; 98: 839-44.
25. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al, for the AFCAPS/TexCAPS Research group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-22.
26. Chew D, Bhatt DL, Robbins MA, Mukherjee D, Raffi M, Schneider JP, et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C reactive protein. Am J Cardiol 2001; 88: 672-4.